BioSpace News Archive

Business

Thomas Hecht to Chair Orion Biotechnology’s Board of Directors

Orion Biotechnology Canada Ltd. announced that Dr. Thomas Hecht has been appointed Chairman of its Board of Directors.

November 13, 2019
·
2 min read
Policy

Promore Pharma is granted a patent for PXL01 in the US

Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, announced that its subsidiary Pergamum AB was granted a patent in the US for the pharmaceutical formulation of the product candidate PXL01.

November 13, 2019
·
3 min read
Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment

Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting

November 13, 2019
·
16 min read
Biotech Bay

Atara Biotherapeutics to present tab-cel® long-term clinical outcomes from a multicenter EAP study for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) at the 61st ASH Annual Meeting

26 relapsed/refractory EBV+ PTLD patients were treated in a multicenter tab-cel® EAP study including a subgroup of 22 patients who would have likely met eligibility criteria for Atara’s ongoing tab‑cel® Phase 3 studies

November 13, 2019
·
11 min read
Biotech Beach

Tracking and Delivering Targeted Cancer Therapeutics with Microbubbles and Sound Waves

Biomedical engineers at the University of Southern California developed a method using ultrasound to control and track drug release.

November 13, 2019
·
2 min read
·
Mark Terry
Deals

Merck Snaps Up Preclinical Neurodegenerative Asset in $576 Million Buy

Merck plunked down $576 million to acquire San Diego-based Calporta to gain access to preclinical TRPML1 agonists that are seen as potential treatments for neurodegenerative disorders such as Alzheimer’s or Parkinson’s.

November 13, 2019
·
2 min read
·
Alex Keown
Drug Development

Kiadis to Restructure Months After Acquiring CytoSen Therapeutics

The company will discontinue development of its lead T-cell asset, ATIR101, halt its ongoing Phase III trial and lay off half its staff.

November 13, 2019
·
2 min read
·
Alex Keown
BioForest

Weill Neurohub Will Promote Cross-Institutional Collaboration in Brain Trauma and Neurodegenerative Diseases

The Weill Family Foundation, University of California, Berkeley, University of California, San Francisco and the University of Washington launched the Weill Neurohub with a $106 million gift.

November 13, 2019
·
3 min read
·
Mark Terry
Is DNA the Data Storage of the Future?

DNA is structurally suited to storing information for extended periods of time, given its half-life of 521 years.

November 13, 2019
·
4 min read
·
David Kirk
Drug Development

GSK’s Nucala Hits the Mark in Phase III HES Trial, Setting Up Potential Approval

HES is a rare group of inflammatory disorders that affects approximately 20,000 people around the world.

November 13, 2019
·
2 min read
·
Alex Keown